



Attorney Docket No.: 6413.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ebdrup et al.

Serial No.: 10/614,233

Group Art Unit: To be assigned

Filed: July 7, 2003

Examiner: To be assigned

For: **Pharmaceutical Use of Boronic Acids and Esters Thereof**

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (4)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on September 2, 2003

Dolly Kapadia
(name of person mailing paper)

Dolly Kapadia
(signature of person mailing paper)



Attorney Docket No.: 6413.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ebdrup et al.

Application No.: 10/614,233

Group Art Unit: To be assigned

Filed: July 7, 2003

Examiner: To be assigned

For: **Pharmaceutical Use of Boronic Acids and Esters Thereof**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. U.S. Patent no. 6,075,014
2. WO 98/31688 A1
3. FR 2758329
4. EP 792883

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: September 2, 2003


Respectfully submitted,



Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE


 FORM PTO-1449
 (Rev. 2-92)

 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE
Atty. Docket No. **6413.200-US**Serial No. **10/614,233**
 INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Ebdrup et al.**Filing Date **July 7, 2003**Group **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,075,014	6/13/00	Weston et al.	514	64	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/31688 A1	7/23/98					
	FR 2758329	1/16/97				Ab- stract	
	EP 792883	3/9/97				Ab- stract	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.